FIGURE 6.

CK548 inhibits HIV-1 latent infection of resting CD4 T cells. A, resting CD4 T cells were pre-treated with CK548 for 1 h, and then infected with HIV-1 for 2 h. Cells were washed, cultured for 5 days in the presence of CK548, and then activated with anti-CD3/CD28 beads (4 beads per cell). Viral replication was monitored by p24 release. B and C, effects of CK548 on T cell activation measured by CD25 and CD69 up-regulation. Resting CD4 T cells were treated with CK548 at different dosages for 1 day, and then stimulated with anti-CD3/CD28 beads (4 beads per cell) for 24 h. Up-regulation of the CD25 and CD69 receptors following stimulation was measured by surface staining with PE-labeled monoclonal antibodies against either CD25 (B) or CD69 (C). Shown are the results from flow cytometry, demonstrating that CK548 did not inhibit T cell activation at dosages at or below 25 μm.